Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.642
Peer-review started: April 30, 2020
First decision: May 15, 2020
Revised: May 18, 2020
Accepted: May 21, 2020
Article in press: May 21, 2020
Published online: June 15, 2020
Mucinous cystic neoplasm (MCN) of the pancreas is characterized by mucin-producing columnar epithelium and dense ovarian-type stroma and at risk for malignant transformation. Early diagnosis and treatment of MCN are particularly important.
We comprehensively evaluated the clinical and pathological characteristics of MCA and MCC and further explored effective treatment strategy.
In this study, the authors aimed to investigate the clinical characteristics of and management strategies for pancreatic mucinous cystadenoma (MCA) and mucinous cystadenocarcinomas (MCC).
The clinical and pathological data of 82 patients with pancreatic MCA and MCC who underwent surgical resection at our department between April 2015 and March 2019 were retrospectively analyzed.
Of the 82 patients included in this study, 70 had MCA and 12 had MCC. Tumor size of MCC was larger than that of MCA. Age and serum levels of tumor markers carcinoembryonic antigen (CEA), CA19-9, and CA12-5 were significantly higher in MCC than in MCA patients. MCA tumor size was positively correlated with serum CA19-9 levels. Compared with MCC, MCA had a higher minimally invasive surgery rate. In the MCA group, the rate of major complications was 5.7% and that of clinically relevant pancreatic fistula was 8.6%; the corresponding rates in the MCC group were 16.7% and 16.7%.
Tumor size, age, and serum CEA, CA19-9, and CA12-5 levels may contribute to management of patients with MCN. Surgical resection is the primary treatment modality for MCC and MCA.
Age and serum CEA, CA19-9, and CA125 levels can be used as an effective tool to help clinicians quickly identify MCC and MCA. Minimally invasive surgical resection is an effective treatment for MCC and MCA.